1. Introduction {#sec1}
===============

Parkinson\'s disease (PD) is the second most common neurodegenerative disorder. PD is defined by the presence of bradykinesia and at least one of the following symptoms: muscular rigidity, rest tremor, or postural instability. It is characterized by the cardinal motor symptoms of resting tremor, rigidity, bradykinesia, and postural instability, and a variety of nonmotor symptoms, such as olfactory dysfunction, psychiatric disorders, autonomic disturbances, and cognitive decline, among others. Although the etiology of PD has not been fully elucidated, it is thought to be the result of the interaction between genetic and environmental factors \[[@B1]\]. A number of candidate genes involved in PD etiology have been identified. Among them, mutations in the leucine-rich repeat kinase 2 gene (*LRRK2*) have been consistently reported to be the most frequent known cause of both sporadic and familial PD \[[@B2]\]. In particular, the G2385R polymorphism in *LRRK2* is an important genetic risk factor for PD in Asian individuals, as evidenced by various independent studies.

In recent years, genotype-phenotype correlation studies have suggested that PD patients with the *LRRK2* G2385R variant may exhibit some unique clinical characteristics, although some results were contradictory. Available studies have found that *LRRK2* G2385R carriers had a higher frequency of family history \[[@B3]\], longer disease duration \[[@B4]\], a lower age at onset \[[@B5]\], a higher proportion of postural instability and gait disorder (PIGD) phenotype \[[@B6]\], and a higher Mini-Mental State Examination (MMSE) score than PD patients who do not carry the *LRRK2* G2385R \[[@B6]\]. Moreover, a higher levodopa-equivalent dose (LED) and a higher proportion of levodopa-induced complications, including motor fluctuations and dyskinesia, were also observed in PD patients with the *LRRK2* G2385R variant in some studies \[[@B6], [@B7]\]. However, several other findings indicated that neither demographic data nor clinical presentation differed significantly between *LRRK2* G2385R carriers and noncarriers \[[@B8]--[@B10]\].

Taken together, there is no consensus about the relationship between *LRRK2* G2385R and clinical manifestations of PD patients. Here, we performed a meta-analysis to investigate whether *LRRK*2 G2385R was associated with the clinical presentation of PD.

2. Methods {#sec2}
==========

The literature search strategies, inclusion and exclusion criteria, outcome measurements, and methods of statistical analysis were completed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis and Meta-analysis of Observational Studies in Epidemiology recommendations for study reporting \[[@B11]--[@B13]\]. All analyses were based on previously published studies; thus, ethical approval and patient consent were not required.

2.1. Literature Search Strategy {#sec2.1}
-------------------------------

A literature search was performed for publications up to September 2017 without restriction to regions, publication types, or languages. The primary sources were the electronic databases of PubMed, Web of Science, EMBASE, CNKI, and WANFANG. The following terms and their combinations were searched in \[All Fields\]: Parkinson disease, Parkinson\'s disease, Parkinson^∗^, LRRK2 G2385R, LRRK2 Gly2385Arg, LRRK2 c.7153G\>A. The reference lists of the included studies were screened to find further relevant studies.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies were selected when they met all the following criteria and the following studies were included if they met any of the following criteria: (1) observational studies, such as case-control studies and cohort studies; (2) comparative studies, which had to include an *LRRK2* G2385R-carrier PD group and an *LRRK2* G2385R-noncarrier PD group; (3) studies of association between specific clinical features (motor symptoms and nonmotor symptoms) and the *LRRK2* G2385R mutation; and (4) the diagnosis of PD had to be made according to the United Kingdom Parkinson Disease Society Brain Bank criteria. The following studies were excluded: (1) review articles, case reports, editorials; (2) duplicated reports (when multiple reports studying the same participants were published, the latest or most complete report was included); (3) studies with incomplete data, which included studies that did not compare *LRRK2* G2385R-carrier and *LRRK2* G2385R-noncarrier PD patients; and (4) functional studies, such as animal experiments and cell experiments studies.

2.3. Data Extraction and Outcomes of Interest {#sec2.3}
---------------------------------------------

Data from the included studies were extracted and summarized independently by two authors (Wei Di and Zhi-yong Zeng). Any disagreements were resolved by the senior authors (Jing-yan Li and Hua Lv). The primary outcomes were the comparison of clinical characteristics including motor symptoms and nonmotor symptoms in the two study groups (*LRRK2* G2385R carriers and noncarriers).

2.4. Quality Assessment and Statistical Analysis {#sec2.4}
------------------------------------------------

The quality of selected studies was evaluated using the Newcastle−Ottawa Quality Assessment Scale (NOS) \[[@B14]\], which included three factors: patient selection, comparability of the study groups, and assessment of outcome. A score of 0--9 was allocated to each study. Studies that achieved six or more points were considered to be of high quality. The assessments were conducted by two authors (Wei Di and Zhi-yong Zeng).

All statistical analyses and graphics were generated using Review Manager 5.3 (Cochrane Collaboration, Oxford, England). The weighted mean difference (MD) and odds ratios (OR) were used to compare continuous and dichotomous variables, respectively. All results were reported with 95% confidence intervals (CIs). Statistical heterogeneity between studies was assessed using the chi-square test with significance set at *P* ≤ 0.10, and heterogeneity was quantified using the *I* ^2^ statistic. The random effect model was used if there was heterogeneity between studies; alternatively, the fixed effect model was used \[[@B15]\]. *Z* tests were conducted to assess the association between the *LRRK2* G2385R variant and clinical characteristics. *P* values \< 0.05 indicated statistically significant differences. Sensitivity analysis was performed in each comparison. Funnel plot analyses were used to screen for potential publication bias.

3. Results {#sec3}
==========

3.1. Characteristics of Eligible Studies {#sec3.1}
----------------------------------------

A total of 359 studies were identified by searching in PubMed, Web of Science, EMBASE, CNKI, and WANFANG electronic databases. Sixteen eligible studies were included in the final statistical analysis \[[@B3]--[@B10], [@B16]--[@B23]\]. The detailed flow chart of study selection and reasons for exclusion are shown in [Figure 1](#fig1){ref-type="fig"}. All publications were full-text articles. Agreement between the two reviewers was 97% for study selection and 94% for quality assessment of trials. The detailed characteristics of all included studies are summarized in [Table 1](#tab1){ref-type="table"}. All studies were performed on Asian individuals. The NOS score of all the included studies were no less than 6, indicating that none of the included studies were of low quality.

3.2. Meta-Analysis Results {#sec3.2}
--------------------------

### 3.2.1. Family History {#sec3.2.1}

PD patients with family history are defined as having at least one first- or second-degree relative with a diagnosis of PD. Five studies assessed the relationship between *LRRK2* G2385R status and family history of PD, and the data showed that a family history of PD was significantly more common in the *LRRK2* G2385R carriers than in the *LRRK2* G2385R noncarriers (OR: 1.98; 95% CI: 1.16−3.39; *P*=0.01) (Supplementary [Figure 1](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.2. Sex Distribution {#sec3.2.2}

Twelve studies included a sex distribution analysis between *LRRK2* G2385R-carrier PD group and *LRRK2* G2385R-noncarrier PD group. There was no significant association between males and *LRRK2* G2385R carrier status (OR = 0.85, 95% CI: 0.70−1.02, *P*=0.08, Supplementary [Figure 2](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.3. Disease Duration {#sec3.2.3}

There were seven studies that mentioned the difference in disease duration between *LRRK2* G2385R-carrier PD patients and *LRRK2* G2385R-noncarrier PD patients. The average disease duration in carriers of the *LRRK2* G2385R was slightly longer than that in noncarriers (MD = 0.47, 95% CI: 0.01−0.93, *P*=0.04, Supplementary [Figure 3](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.4. Age at Onset {#sec3.2.4}

Twelve studies assessed the relationship between *LRRK2* G2385R status and age at onset (AAO) of PD patients. Four studies referred to AAO in early-onset PD patients. Another four studies were concerned with late-onset PD patients. No statistically significant differences were recorded between *LRRK2* G2385R-carrier PD group and *LRRK2* G2385R-noncarrier PD group (mean AAO: MD = −0.06, 95% CI: −0.15 to 0.03, *P*=0.19, Supplementary [Figure 4A](#supplementary-material-1){ref-type="supplementary-material"}; AAO in early-onset PD: MD = −2.43, 95% CI: −0.55 to 5.42, *P*=0.11, Supplementary [Figure 4B](#supplementary-material-1){ref-type="supplementary-material"}; AAO in late-onset PD: MD = −1.54, 95% CI: −3.38 to 0.30, *P*=0.10, Supplementary [Figure 4C](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.5. Initial Symptoms {#sec3.2.5}

Four common initial symptoms, including tremor, rigidity, bradykinesia, and postural instability, were compared between *LRRK2* G2385R-carrier PD group and *LRRK2* G2385R-noncarrier PD group. No significant differences were observed (tremor: OR = 1.05, 95% CI: 0.76−1.45, *P*=0.76, Supplementary [Figure 5A](#supplementary-material-1){ref-type="supplementary-material"}; rigidity: OR = 1.14, 95% CI: 0.70−1.86, *P*=0.60, Supplementary [Figure 5B](#supplementary-material-1){ref-type="supplementary-material"}; bradykinesia: OR = 1.17, 95% CI: 0.76−1.79, *P*=0.48, Supplementary [Figure 5C](#supplementary-material-1){ref-type="supplementary-material"}; postural instability: OR = 0.97, 95% CI: 0.39−2.39, *P*=0.94, Supplementary [Figure 5D](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.6. Disease Severity {#sec3.2.6}

The H-Y and UPDRS-III were commonly used to evaluate disease severity. Six studies involved H-Y analysis, and five studies involved UPDRS-III analysis in *LRRK2* G2385R-carrier PD and *LRRK2* G2385R-noncarrier PD patients. No significant differences were discovered (H-Y: MD = −0.09, 95% CI: −0.20 to 0.01, *P*=0.07, Supplementary [Figure 6A](#supplementary-material-1){ref-type="supplementary-material"}; UPDRS-III: MD = −1.35, 95% CI: −2.82 to 0.11, *P*=0.07, Supplementary [Figure 6B](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.7. Motor Symptoms {#sec3.2.7}

Tremor, rigidity, bradykinesia, PIGD are the main motor manifestations of PD patients. Four studies assessed the relationship between *LRRK2* G2385R status and the tremor phenotype of PD patients. Three studies focused on the PIGD phenotype, and two studies analyzed rigidity and bradykinesia phenotype. The meta-analysis results of these studies showed that there were no significant differences in the above motor phenotypes in the *LRRK2* G2385R-carrier PD group compared to *LRRK2* G2385R-noncarrier PD group (tremor: OR = 0.88, 95% CI: 0.40−1.91, *P*=0.74, Supplementary [Figure 7A](#supplementary-material-1){ref-type="supplementary-material"}; rigidity: OR = 1.59, 95% CI: 0.48−5.27, *P*=0.45, Supplementary [Figure 7B](#supplementary-material-1){ref-type="supplementary-material"}; bradykinesia: OR = 0.43, 95% CI: 0.15−1.24, *P*=0.12, Supplementary [Figure 7C](#supplementary-material-1){ref-type="supplementary-material"}; PIGD: OR = 1.24, 95% CI: 0.48−3.23, *P*=0.66, Supplementary [Figure 7D](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.8. Nonmotor Symptoms {#sec3.2.8}

Only MMSE scores and the proportion of patients with depression were assessed owing to incomplete data about other nonmotor symptoms. Three studies included an MMSE score analysis in both groups and showed a significantly higher MMSE score in the *LRRK2* G2385R-carrier PD group than in the *LRRK2* G2385R-noncarrier PD group (MD = 1.02, 95% CI: 0.43--1.62, *P*=0.0007, Supplementary [Figure 8A](#supplementary-material-1){ref-type="supplementary-material"}). Two studies included a depression analysis, but there was no significant association between depression and *LRRK2* G2385R status (OR = 1.46, 95% CI: 0.90−2.37, *P*=0.13, Supplementary [Figure 8B](#supplementary-material-1){ref-type="supplementary-material"}).

### 3.2.9. Levodopa Therapy and Related Complications {#sec3.2.9}

There were some studies that mentioned the LED and related complications, including motor fluctuation and dyskinesia. The meta-analysis results of these studies showed no significant differences for LED, motor fluctuation, or dyskinesia between the *LRRK2* G2385R-carrier PD group and the *LRRK2* G2385R-noncarrier PD group (LED: MD = 0.14, 95% CI: −0.06 to 0.33, *P*=0.17, Supplementary [Figure 9A](#supplementary-material-1){ref-type="supplementary-material"}; motor fluctuation: OR = 1.73, 95% CI: 0.99−3.01, *P*=0.05, Supplementary [Figure 9B](#supplementary-material-1){ref-type="supplementary-material"}; dyskinesia: OR = 1.26, 95% CI: 0.63−2.54, *P*=0.52, Supplementary [Figure 9C](#supplementary-material-1){ref-type="supplementary-material"}).

Taken together, the *LRRK2* G2385R-carrier PD group more often presented a family history of PD and had a longer disease duration and a higher MMSE score than the *LRRK2* G2385R-noncarrier PD group. However, *LRRK2* G2385R carriers showed no significant differences in sex distribution, AAO, initial symptoms, motor symptoms and grade of severity, depression, or LED and levodopa-related complications compared to *LRRK2* G2385R noncarriers. The results of the meta-analysis are summarized in [Table 2](#tab2){ref-type="table"}.

3.3. Sensitivity Analysis and Publication Bias {#sec3.3}
----------------------------------------------

A sensitivity analysis was made in comparison with significant heterogeneity among the studies. When the heterogeneity among the studies was significant, we performed sensitivity analyses by excluding the relatively low-quality studies; the same results were obtained. Therefore, we can conclude that the sensitivity is low and that the results are reliable. As there were fewer than 10 high-quality studies in most comparisons in our meta-analysis, an accurate publication bias assessment could not be performed. However, we completed a funnel plot to estimate publication bias. There were no asymmetries in the funnel plot and no significant publication biases of the meta-analysis.

4. Discussion {#sec4}
=============

In this meta-analysis, we extensively analyzed the relationship between *LRRK2* G2385R carrier status and clinical manifestations of PD in an Asian population. The *LRRK2* G2385R-carrier PD group significantly more often had a family history of PD than did the *LRRK2* G2385R-noncarrier PD group. The average disease duration in the *LRRK2* G2385R-carrier PD group was slightly longer than that in the *LRRK2* G2385R-noncarrier PD group. The mean MMSE score was significantly lower in the *LRRK2* G2385R-noncarrier PD group than in the *LRRK2* G2385R-carrier PD group.

Additionally, we observed that there were no significant differences in most of the clinical characteristics, including sex distribution, AAO, initial symptoms, motor symptoms and grade of severity, depression, and LED and levodopa-related complications between *LRRK2* G2385R-carrier and *LRRK2* G2385R-noncarrier PD patients. These results indicated that PD patients carrying a *LRRK2* G2385R mutation is associated with a significantly overlapping phenotype when compared with idiopathic PD. This finding is in line with those of previous studies reporting that G2019S carrier patients exhibit clinical features quite similar to those of noncarriers, with some mild differences \[[@B24]--[@B26]\]. One possible reason for this was that a broad spectrum of clinical characteristics may be caused by gene-gene interaction or gene-environment interactions, affecting the genotype and progression of the disease.

Nonmotor symptoms in PD are quite common and contribute to the patient\'s disability \[[@B27]\]. Associations between the genotype and nonmotor symptoms in PD patients have attracted research attention in recent years. To date, a few studies have focused mainly on several specific nonmotor symptoms, rather than on the general nonmotor symptom profile. Therefore, we failed to find sufficient data to assess the nonmotor symptoms of PD patients in the context of *LRRK2* G2385R status. For MMSE scores, given that only three published papers were included in the meta-analysis, a publication bias is likely to be present. A detailed clinical characterization of PD patients carrying *LRRK2* variants is warranted.

The NOS scores of all included publications were rated from 6 points to 9 points, providing a reliable bottom for the current analysis. No statistically significant publication bias or heterogeneity between different studies was detected in our meta-analysis. However, several limitations may have influenced the precision of our results. First, given that the number of included studies was limited, publication bias could potentially occur, even though we used various searching approaches and statistical analyses to minimize the publication bias. Second, although this meta-analysis included all the published case-control cohorts, some unpublished results may have been neglected.

5. Conclusion {#sec5}
=============

In conclusion, our study suggested that most of the clinical characteristics of PD patients with the *LRRK2* G2385R mutation were similar to those of *LRRK2* G2385R noncarriers among Asian individuals, except for a more common family history, relatively longer disease duration, and higher MMSE scores in the *LRRK2* G2385R carriers. These findings strengthen our understanding of the clinical and genetic heterogeneity of PD and may have implications for diagnosis and therapy of PD. However, further larger samples and multicenter cooperative studies in different populations are warranted to clarify the relevance between the *LRRK2* G2385R genotype and clinical phenotype of PD.
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###### 

Supplementary Figure 1: forest plot of family history in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD. Supplementary Figure 2: forest plot of gender distribution (male) in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD. Supplementary Figure 3: forest plot of disease duration in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD. Supplementary Figure 4: forest plot of age at onset in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD---(A) mean AAO, (B) AAO in early-onset PD, and (C) AAO in late-onset PD. Supplementary Figure 5: forest plot of initial symptoms in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD---(A) tremor, (B) rigidity, (C) bradykinesia, and (D) postural instability. Supplementary Figure 6: forest plot of motor symptoms severity in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD---(A) H-Y and (B) UPDRS. Supplementary Figure 7: forest plot of motor symptoms in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD---(A) tremor, (B) rigidity, (C) bradykinesia, and (D) PIGD. Supplementary Figure 8: forest plot of nonmotor symptoms in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD---(A) MMSE and (B) depression. Supplementary Figure 9: forest plot of levodopa therapy and related complications in *LRRK2* G2385R+PD and *LRRK2* G2385R-PD---(A) levodopa-equivalent dose, (B) motor fluctuation, and (C) dyskinesia.

###### 

Click here for additional data file.
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###### 

Characteristics of included publication.

  Article                      Country       *LRRK2* G2385R   Number   Family history   Sex (male)          Disease duration   AAO (*n*)          AAO (EOPD)         AAO (LOPD) (*n*)   Initial symptom   H-Y   UPDRS-III     Motor symptom   Nonmotor symptoms   LED (mg)        Motor fluctuation   Dyskinesia   NOS score                                                                            
  ---------------------------- ------------- ---------------- -------- ---------------- ------------------- ------------------ ------------------ ------------------ ------------------ ----------------- ----- ------------- --------------- ------------------- --------------- ------------------- ------------ -------------- ----- ----------------- --------------- ----------------- ----- ----- ---
  An et al. \[[@B5]\]          China         Carriers         71       ---              40                  ---                52.75 ± 9.84       42.96 ± 7.23       58.40 ± 5.93       37                ---   ---           ---             2.16 ± 0.91         ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   8
  noncarriers                  529           ---              314      ---              56.32 ± 11.26       40.81 ± 7.35       61.07 ± 7.27       263                ---                ---               ---   2.33 ± 0.98   ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---                           
                                                                                                                                                                                                                                                                                                                                                                                                        
  Cai et al. \[[@B10]\]        China         Carriers         49       ---              28                  5.18 ± 2.58        56.8 ± 10.7        41.6 ± 5.91        61.3 ± 7.04        34                24    0             18              2.47 ± 0.89         21.4 ± 8.78     ---                 ---          ---            ---   ---               ---             ---               ---   ---   8
  noncarriers                  461           ---              275      4.92 ± 3.36      58.6 ± 11.0         42.9 ± 5.5         63.2 ± 7.33        299                224                9                 168   2.57 ± 0.93   22.1 ± 8.35     ---                 ---             ---                 ---          ---            ---   ---               ---             ---                           
                                                                                                                                                                                                                                                                                                                                                                                                        
  Cao et al. \[[@B7]\]         China         Carriers         14       0                5                   8.57 ± 8.71        57.1 ± 11.0        ---                ---                8                 7     5             7               1.7 ± 0.4           19.6 ± 5.1      ---                 ---          ---            ---   ---               ---             ---               ---   3     7
  noncarriers                  221           13               128      5.52 ± 4.81      54.4 ± 13.4         ---                ---                134                102                64                83    2.0 ± 0.8     20.5 ± 7.3      ---                 ---             ---                 ---          ---            ---   ---               ---             57                            
                                                                                                                                                                                                                                                                                                                                                                                                        
  Cao et al. \[[@B16]\]        China         Carriers         25       ---              16                  ---                ---                ---                ---                ---               ---   ---           ---             2.2 ± 0.8           ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   5
  noncarriers                  43            ---              28       ---              ---                 ---                ---                ---                ---                ---               ---   2.4 ± 0.74    ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---                           
                                                                                                                                                                                                                                                                                                                                                                                                        
  Chan et al. \[[@B17]\]       Hong Kong     Carriers         ---      ---              ---                 ---                ---                42.7 ± 2.3 (3)     74.3 ± 4.9 (4)     ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   6
  China                        noncarriers   ---              ---      ---              ---                 ---                38.3 ± 6.6 (34)    69.2 ± 10.7 (44)   ---                ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---               ---         
                                                                                                                                                                                                                                                                                                                                                                                                        
  Di Fonzo et al. \[[@B18]\]   Taiwan        Carriers         61       ---              34                  13.4 ± 6.2         53.2 ± 12.5        ---                ---                ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   8
  China                        noncarriers   547              ---      328              11.2 ± 6.0          55.0 ± 11.9        ---                ---                ---                ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---               ---         
                                                                                                                                                                                                                                                                                                                                                                                                        
  Farrer et al. \[[@B3]\]      Taiwan        Carriers         34       6                18                  7.3 ± 5.4          54.9 ± 11.8        ---                ---                ---               ---   ---           ---             ---                 ---             24                  32           30             12    ---               ---             457.6 ± 246.6     12    13    8
  China                        noncarriers   376              20       214              7.2 ± 4.6           58.0 ± 11.7        ---                                   ---                ---               ---   ---           ---             ---                 258             343                 365          150            ---   ---               444.6 ± 270.9   122               117         
                                                                                                                                                                                                                                                                                                                                                                                                        
  Funayama et al. \[[@B20]\]   Japan         Carriers         ---      ---              ---                 ---                54.0 ± 10.6 (50)   42.5 ± 5.8 (17)    59.9 ± 7.0 (33)    ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   7
  noncarriers                  ---           ---              ---      ---              50.3 ± 14.9 (389)   37.1 ± 9.4 (180)   61.6 ± 7.8 (209)   ---                ---                ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---                           
                                                                                                                                                                                                                                                                                                                                                                                                        
  Fung et al. \[[@B22]\]       Taiwan        Carriers         27       ---              ---                 ---                61.5 ± 11.3        ---                ---                ---               ---   ---           ---             ---                 ---             26                  26           27             ---   ---               ---             ---               ---   ---   7
  China                        noncarriers   278              ---      ---              ---                 61.9 ± 10.5                           ---                ---                ---               ---   ---           ---             ---                 252             261                 269          ---            ---   ---               ---             ---               ---         
                                                                                                                                                                                                                                                                                                                                                                                                        
  Fu et al. \[[@B19]\]         China         Carriers         37       8                21                  ---                55 ± 11.7          ---                ---                21                11    1             3               ---                 ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   7
  noncarriers                  365           51               201      ---              55.0 ± 11.0         ---                ---                220                81                 16                26    ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---                           
                                                                                                                                                                                                                                                                                                                                                                                                        
  Gao et al. \[[@B7]\]         China         Carriers         36       2                21                  4.1 ± 2.7          60.5 ± 10.4        ---                ---                ---               ---   ---           ---             ---                 ---             16                  ---          ---            16    27.2 ± 3.4        ---             ---               13    6     6
  noncarriers                  139           10               73       3.8 ± 3.2        58.2 ± 8.8          ---                ---                ---                ---                ---               ---   ---           ---             55                  ---             ---                 73           25.3 ± 4.0     ---   ---               15              6                             
                                                                                                                                                                                                                                                                                                                                                                                                        
  Hong et al. \[[@B21]\]       Korean        Carriers         23       ---              7                   3.8 ± 3.1          ---                ---                ---                ---               ---   ---           ---             ---                 19.8 ± 11.2     ---                 ---          ---            ---   25.6 ± 4.4        5               ---               ---   ---   7
  noncarriers                  276           ---              136      4.2 ± 3.3        ---                 ---                ---                ---                ---                ---               ---   ---           23.6 ± 8.7      ---                 ---             ---                 ---          25.0 ± 4.0     56    ---               ---             ---                           
                                                                                                                                                                                                                                                                                                                                                                                                        
  Kim et al. \[[@B9]\]         Korean        Carriers         82       ---              35                                     55.3 ± 11.5        ---                ---                ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   9
  noncarriers                  841           ---              373                       54.7 ± 10.8         ---                ---                ---                ---                ---               ---   ---           ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---                           
                                                                                                                                                                                                                                                                                                                                                                                                        
  Sun et al. \[[@B6]\]         China         Carriers         76       ---              37                  6.57 ± 4.21        55.57 ± 8.78       ---                ---                ---               ---   ---           ---             2.15 ± 0.83         24.55 ± 12.08   29                  ---          ---            43    27.78 ± 2.68      27              553.67 ± 329.84   27    4     7
  noncarriers                  225           ---              125      5.73 ± 3.55      57.05 ± 8.92        ---                ---                ---                ---                ---               ---   2.08 ± 0.81   26.52 ± 12.64   140                 ---             ---                 69           26.96 ± 2.92   58    467.71 ± 286.34   50              8                             
                                                                                                                                                                                                                                                                                                                                                                                                        
  Tan et al. \[[@B8]\]         Singapore     Carriers         33       5                16                  ---                59.0. ± 11.0       ---                ---                ---               ---   ---           ---             ---                 26.0 ± 11.0     ---                 ---          ---            ---   ---               ---             467.0 ± 275.0     ---   7     5
  noncarriers                  29            0                18       ---              59.0 ± 10.0                            ---                ---                ---                ---               ---   ---           27.0 ± 11.0     ---                 ---             ---                 ---          ---            ---   537.0 ± 287.0     ---             11                            
                                                                                                                                                                                                                                                                                                                                                                                                        
  Zhou et al. \[[@B23]\]       China         Carriers         26       ---              ---                 ---                ---                ---                ---                ---               ---   ---           ---             1.82 ± 0.58         ---             ---                 ---          ---            ---   ---               ---             ---               ---   ---   7
  noncarriers                  176           ---              ---      ---              ---                 ---                ---                ---                ---                ---               ---   1.76 ± 0.76   ---             ---                 ---             ---                 ---          ---            ---   ---               ---             ---                           

###### 

Summarized results of the meta-analysis.

  Subjects                          Effect model   MD/OR (95% CI)            *P* value   Study heterogeneity             
  --------------------------------- -------------- ------------------------- ----------- --------------------- ---- ---- --------
  Family history                    Fixed          1.98 \[1.16--3.39\]       0.01        5.42                  4    26   0.25
  Gender (male)                     Fixed          0.85 \[0.70--1.02\]       0.08        6.09                  11   0    0.87
  Disease duration                  Fixed          0.47 \[0.01--0.93\]       0.04        8.16                  6    27   0.23
  AAO                               Fixed          −0.06 \[−0.15 to 0.03\]   0.19        16.32                 11   33   0.13
  AAO (early-onset)                 Random         2.43 \[−0.55 to 5.42\]    0.11        19.47                 3    85   0.0002
  AAO (late-onset)                  Random         −1.54 \[−3.38 to 0.30\]   0.10        6.67                  3    55   0.08
  Initial symptoms---tremor         Fixed          1.05 \[0.76--1.45\]       0.76        0.70                  3    0    0.87
  Initial symptoms---rigidity       Fixed          1.14 \[0.70--1.86\]       0.60        0.61                  2    0    0.74
  Initial symptoms---bradykinesia   Fixed          1.17 \[0.76--1.79\]       0.48        0.61                  2    0    0.74
  Initial symptoms---PI             Fixed          0.97 \[0.39--2.39\]       0.94        0.78                  2    0    0.68
  H-Y                               Fixed          −0.09 \[−0.20 to 0.01\]   0.07        7.39                  5    32   0.19
  UPDRS-III                         Fixed          −1.35 \[−2.82 to 0.11\]   0.07        1.56                  4    0    0.82
  Motor symptoms---tremor           Random         0.88 \[0.40--1.91\]       0.74        10.41                 3    71   0.02
  Motor symptoms---rigidity         Fixed          1.59 \[0.48--5.27\]       0.45        0.01                  1    0    0.94
  Motor symptoms---bradykinesia     Fixed          0.43 \[0.15--1.24\]       0.12        1.90                  1    47   0.17
  Motor symptoms---PIGD             Random         1.24 \[0.48--3.23\]       0.66        12.47                 2    84   0.002
  MMSE                              Fixed          1.02 \[0.43--1.62\]       0.0007      2.27                  2    12   0.32
  Depression                        Fixed          1.46 \[0.90--2.37\]       0.13        0.39                  1    0    0.53
  LED                               Fixed          0.14 \[−0.06 to 0.33\]    0.17        3.78                  2    47   0.15
  Motor fluctuation                 Random         1.73 \[0.99--3.01\]       0.05        7.52                  2    73   0.02
  Dyskinesia                        Random         1.26 \[0.63--2.54\]       0.52        8.26                  4    52   0.08

[^1]: Academic Editor: Cristine Alves da Costa
